Adaptive Biotechnologies Corporation (NasdaqGS: ADPT)
Health Care · Life Sciences Tools & Services · US
$26.25
+2.74% today · +107.2% 1Y
Adaptive Biotechnologies Corporation (NasdaqGS: ADPT) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $4.19B and employs 624 people.
Over the last twelve months the share price has gained 107.2%, trading between 12.00 and 26.16.
Tweenvest scores Adaptive Biotechnologies Corporation across four factors: quality 28/100, value 37/100, growth 95/100. Its strongest factor is growth.
ADPT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.19B
- Revenue (TTM)
- $308.08M
- P/E
- —
- EPS
- -0.41
- Dividend yield
- —
- Beta (5Y)
- 2.09
- 52-week high
- $26.16
- 52-week low
- $12.00
- Avg volume (3M)
- —
- Shares outstanding
- 159.60M
- Employees
- 624
- Next earnings
- —
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
- ISIN
- US00650F1093
- Founded
- 2009
- Listed since
- Jun 27, 2019
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.26B | $628.15 | -0.09% |
| Danaher CorporationNYSE: DHR | $151.82B | $215.97 | +0.40% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $71.35B | CN¥161.00 | +3.31% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.65B | CHF593.80 | +1.02% |
| Agilent Technologies, Inc.NYSE: A | $43.71B | $154.77 | +0.87% |
| IQVIA Holdings Inc.NYSE: IQV | $42.70B | $259.42 | -0.32% |
| Waters CorporationNYSE: WAT | $40.72B | $414.44 | +0.90% |
Figures last refreshed Aug 18, 2026.